A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Public ClinicalTrials.gov record NCT01192906. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Study identification
- NCT ID
- NCT01192906
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 624 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- bitopertin [RO4917838] Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2010
- Primary completion
- Jun 30, 2014
- Completion
- Jun 30, 2014
- Last update posted
- Nov 1, 2016
2010 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Carson | California | 90746 | — |
| Not listed | Oceanside | California | 92056 | — |
| Not listed | San Diego | California | 92121 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | Hartford | Connecticut | 06106 | — |
| Not listed | Norwalk | Connecticut | 06851 | — |
| Not listed | North Miami | Florida | 33161 | — |
| Not listed | Atlanta | Georgia | 30328 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Hoffman Estates | Illinois | 60169 | — |
| Not listed | Joliet | Illinois | 60435 | — |
| Not listed | Lake Charles | Louisiana | 70601 | — |
| Not listed | Shreveport | Louisiana | 71104-2136 | — |
| Not listed | St Louis | Missouri | 63128 | — |
| Not listed | Omahac | Nebraska | 68131 | — |
| Not listed | Cedarhurst | New York | 11516 | — |
| Not listed | Jamaica | New York | 11418 | — |
| Not listed | Rochester | New York | 14623 | — |
| Not listed | Allentown | Pennsylvania | 18104 | — |
| Not listed | Norristown | Pennsylvania | 19403 | — |
| Not listed | Philadelphia | Pennsylvania | 19139 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01192906, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01192906 live on ClinicalTrials.gov.